Research programme: HIV-1 infection therapeutics - Cocrystal Pharma

Drug Profile

Research programme: HIV-1 infection therapeutics - Cocrystal Pharma

Latest Information Update: 27 Nov 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator RFS Pharma LLC
  • Developer Cocrystal Pharma Inc; Emory University; University of Pittsburgh
  • Class
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical HIV-1 infections

Most Recent Events

  • 25 Nov 2014 RFS Pharma has merged with Cocrystal Pharma Inc to form Advanced Antiviral Development Organization
  • 11 Feb 2009 Antimicrobial data from a preclinical trial in HIV-1 infections presented at the 16th Conference on Retroviruses and Opportunistic Infections (CROI-2009)
  • 06 Feb 2008 Antimicrobial data from a preclinical trial in HIV-1 infections presented at the 15th Conference on Retroviruses and Opportunistic Infections (CROI-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top